Invivyd, Inc. (formerly Adagio Therapeutics, Inc.) — FY 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. The filing was submitted under Adagio Therapeutics, Inc. and ticker ADGI; the requested company name, Invivyd, does not appear as the registrant in this filing. The 2020 comparison covers only June 3, 2020 (inception) through December 31, 2020, so it is not a full-year comparable period.
Business context
The company was a clinical-stage biopharmaceutical business focused on infectious diseases. Its lead candidate, adintrevimab, was being studied for COVID-19 prevention and treatment. The company had no approved products and had generated no product revenue.
Financial and liquidity highlights
| Metric | FY 2021 / December 31, 2021 | Comparison / context |
|---|---|---|
| Revenue | None | No product sales or other revenue reported. |
| Research and development expense | $182.9 million | $22.0 million in the 2020 inception period; higher 2021 spending largely reflected clinical trials and manufacturing. |
| Acquired in-process R&D expense | $7.5 million | $40.1 million in the 2020 inception period; 2021 expense reflected Adimab milestone payments. |
| Selling, general and administrative expense | $36.5 million | $3.2 million in the 2020 inception period. |
| Net loss | $226.8 million | $65.3 million in the 2020 inception period. Accumulated deficit was $292.1 million. |
| Operating cash flow | $(184.7) million | Cash used in operations; reported cash flow was affected by non-cash items and working-capital movements. |
| Cash and cash equivalents; marketable securities | $542.2 million; $49.2 million | $591.4 million combined at year-end, versus $115.0 million cash and no marketable securities at December 31, 2020. |
| Liabilities and debt | $62.1 million total liabilities | Primarily accounts payable and accrued expenses. The filing reports no borrowings or debt balance. |
| Contract commitments | $139.5 million minimum non-cancelable manufacturing purchases | Payments were scheduled for 2022–2023, primarily to WuXi. |
Operating margins are not meaningful because the company had no revenue. The company reported $118,000 of other income, primarily reflecting interest income offset by amortization of marketable-security premiums. It had no income tax benefit, with a full valuation allowance against deferred tax assets.
Material changes and operating developments
- Research and development expense increased substantially as the company advanced adintrevimab through Phase 2/3 trials and secured manufacturing supply. Adintrevimab-related direct external R&D costs were $136.5 million in 2021.
- The company raised approximately $335.2 million net from its Series C preferred stock financing and approximately $327.5 million net from its August 2021 IPO. Preferred shares converted into common stock at the IPO.
- Enrollment in the EVADE prevention and STAMP treatment trials was paused on January 11, 2022 after Omicron emerged. The filing reports no detectable neutralization of Omicron BA.2 by adintrevimab in authentic-virus assays; activity against BA.1 was reduced.
- Development of ADG10 was discontinued because its neutralization profile was less favorable than adintrevimab’s.
- The company reported a fourth-quarter 2021 net loss of $83.0 million, versus $38.7 million in the first quarter, $44.7 million in the second quarter and $60.4 million in the third quarter.
Outlook, risks, and unusual items
- Management estimated that year-end cash, cash equivalents and marketable securities would fund operating expenses and capital expenditure requirements into the second half of 2024. This was based on assumptions that could prove incorrect; additional funding could be needed.
- Management planned to request U.S. FDA Emergency Use Authorization in the second quarter of 2022 for prevention and treatment, and to discuss a potential BLA path with the FDA. These were plans, not authorizations or approvals.
- In pre-Omicron trial populations, adintrevimab showed statistically significant results: 71% relative risk reduction in pre-exposure prophylaxis, 75% in post-exposure prophylaxis, and 66% in treatment for hospitalization or death through Day 29. These preliminary findings do not establish efficacy against later variants; the Omicron treatment sample was too small to draw conclusions.
- Key risks include variant-driven loss of effectiveness, regulatory uncertainty, competition from other antibodies, antivirals and vaccines, reliance on WuXi as the sole manufacturer, supply-chain and manufacturing constraints, and the possibility of needing additional capital. Some clinical trial sites were in Ukraine, creating potential follow-up and data-integrity risks.
- The company had $139.5 million in non-cancelable manufacturing commitments, in addition to potential future milestone and royalty payments under its Adimab, WuXi and other agreements.
- The filing corrected a previously reported clerical error in second-quarter 2021 loss-per-share figures: quarterly loss per share was corrected to $178.86 and year-to-date loss per share to $663.94. The company concluded the prior financial statements were not materially misstated; the correction did not affect net loss or the balance sheet and cash-flow statements.
- A material weakness in controls over certain R&D and manufacturing-related accruals was reported as remediated by December 31, 2021. Management concluded disclosure controls were effective; the filing did not include management’s annual ICFR assessment or auditor attestation under the applicable transition exemption.
Important facts for investors to verify
- Confirm the registrant and company-name continuity: this filing is for Adagio Therapeutics, Inc., while the request identifies Invivyd, Inc.
- Check subsequent FDA and other regulatory decisions, and whether the planned EUA and BLA discussions occurred.
- Review later clinical evidence by variant, especially whether efficacy was established against Omicron lineages and whether dose changes were needed.
- Assess subsequent cash burn, financing needs, and the assumptions underlying the stated runway into the second half of 2024.
- Verify the status of WuXi supply, the $139.5 million purchase commitments, and manufacturing alternatives or capacity.
- Review subsequent disclosures on leadership changes, internal controls, and the corrected quarterly loss-per-share presentation.